Molecular Correlates of Long-Term Response to Bevacizumab in Glioblastoma
JCO Precision Oncology · 2025
DOI: 10.1200/po-24-00873 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von John L Villano und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Kentucky, Lexington, KY. Hauptthemen laut MEDLINE: Bevacizumab, Glioblastoma, Brain Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE The use of bevacizumab in glioblastoma has been associated with increased progression-free survival and improvement in symptoms and quality of life. There are no clinical indicators on how to choose patients who would benefit the most from this agent. We aim to describe molecular markers in patients with glioblastoma who may benefit from treatment. Methods We analyzed glioblastoma tumor samples that underwent comprehensive molecular profiling analysis at Caris Life Sciences. RESULTS The data set consisted of 3,106 glioblastoma tumor samples, of which 571 were from patients treated with bevacizumab. The majority were males (65%) and older than 60 years. Median survival was 17.5 months in patients receiving bevacizumab. In patients who were treated with bevacizumab for ≥1 year, median survival was 33.8 months, compared with 15 months in those treated for ≤6 months. Patients who received bevacizumab for ≥1 year had higher prevalence of LRIG3 (9% v 1%), CDK4 (22% v 8%), and DDIT3 amplification (14% v 4%), SETD2 mutations (10% v 3%), and MGMT methylation (66% v 32%). EGFR amplification was more frequent in patients who received bevacizumab for ≤6 months (46% v 20%). Multivariate analysis showed that CDK4 amplification was associated with longer time on bevacizumab, and EGFR amplification with shorter time after correcting for age, sex, and other molecular alterations. CONCLUSION CDK4 amplification is a potential genetic biomarker to identify patients who may derive prolonged benefit from bevacizumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Kentucky, Lexington, KY.
- Department of Neurology, University of Kentucky, Lexington, KY.
- Department of Neurosurgery, University of Kentucky, Lexington, KY.
- Department of Neuro-Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX.
- Department of Pharmacy, University of Kentucky, Lexington, KY.
- Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY.
ORCID-Profile: John L Villano, Catherine R Garcia, Shulin Zhang, Jill Kolesar, Farhan A Mirza, Timothy Samec, Stephanie Rock, Santosh Kesari, Emil Lou, Sonikpreet Aulakh, Michael J Glantz, Eric T Wong
Förderung
- NCI NIH HHS
Zitieren
APA
Villano, J. L., Garcia, C. R., Morgan, R. M., Zhang, S., Kolesar, J., Mirza, F. A., Samec, T., Xiu, J., Rock, S., Kesari, S., Lou, E., Aulakh, S., Glantz, M. J., & Wong, E. T. (2025). Molecular Correlates of Long-Term Response to Bevacizumab in Glioblastoma. JCO Precision Oncology. https://doi.org/10.1200/po-24-00873
Vancouver
Villano JL, Garcia CR, Morgan RM, Zhang S, Kolesar J, Mirza FA, et al. Molecular Correlates of Long-Term Response to Bevacizumab in Glioblastoma. JCO Precision Oncology. 2025. doi:10.1200/po-24-00873
BibTeX
@article{Villano2025,
author = {Villano, John L and Garcia, Catherine R and Morgan, Rachael M and Zhang, Shulin and Kolesar, Jill and Mirza, Farhan A and Samec, Timothy and Xiu, Joanne and Rock, Stephanie and Kesari, Santosh and Lou, Emil and Aulakh, Sonikpreet and Glantz, Michael J and Wong, Eric T},
title = {Molecular Correlates of Long-Term Response to Bevacizumab in Glioblastoma},
journal = {JCO Precision Oncology},
year = {2025},
doi = {10.1200/po-24-00873}
}
EUVIMED